Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk
Authors' conclusion
Patients randomized to LD-MTX without systemic rheumatic disease had no clinically meaningful difference in BP compared with placebo.
Study context
- Population
- Patients with known cardiovascular disease (CVD) but without rheumatic diseasemean follow-up 26 months
- Participants
- 2,391 vs 2,395
- Comparison
- Low-dose MTX (LD-MTX) vs placebo
- LD-MTXn = 2,391
- Placebon = 2,395reference
- Primary endpoint
- Longitudinal change in SBP and DBP
Methodological detailsdouble-blind, placebo-controlled, linear mixed model
- Double-blind
- Placebo-controlled
- Linear mixed model
Primary result
As reported in the abstract
Β (SBP)
−0.75 mmHg
95% CI −0.02 to −1.49
LD-MTX
Β (DBP)
−0.56 mmHg
95% CI −0.12 to −1.01
LD-MTX
Original publication
Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk. Rheumatology (Oxford). Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →